Anika Therapeutics Reports 4Q18 Orthobiologic Revenue of $23.8MM, -5.3% vs. 4Q17

By Mike Evers

Anika Therapeutics posts 4Q18 orthobiologic revenue of USD $23.8MM, -5.3% vs. 4Q17, with 2018 full-year orthobiologic revenue of $93.6MM, -0.2% vs. 2017.

Member-Only Content

SUBSCRIBE Login

Product Labels: Viscosupplement

Tags: Revenue Report